SIREN : 520905852
SOLAR MED III is a French company founded 16 years ago, specialized in the sector Activités des sociétés holding. Based in FUVEAU (13710), this company of category ETI shows in 2024 a revenue of 1.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 618 313 € | 1 665 177 € | 1 932 105 € | N/C | N/C | N/C | 1 905 148 € | 1 856 012 € |
| Net income | 339 211 € | 364 811 € | 627 444 € | 427 017 € | 336 899 € | 116 685 € | 268 260 € | 173 815 € |
| EBITDA | 1 246 405 € | 1 304 260 € | 1 558 707 € | N/C | N/C | N/C | 1 595 417 € | 1 516 301 € |
| Net margin | 21.0% | 21.9% | 32.5% | N/C | N/C | N/C | 14.1% | 9.4% |
In 2024, SOLAR MED III achieves revenue of 1.6 M€. Activity remains stable over the period (CAGR: -1.7%). Slight decline of -3% vs 2023. After deducting consumption (0 €), gross margin stands at 1.6 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.2 M€, representing 77.0% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 339 k€, i.e. 21.0% of revenue. This profit can be retained or distributed to shareholders.
1 618 313 €
1 618 313 €
1 246 405 €
574 652 €
339 211 €
77.0%
The debt ratio (= Financial debt / Equity x 100) stands at 1035%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 9%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 64.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
1035.415%
8.706%
64.179%
5.575
39.3%
In 2024, the debt ratio of SOLAR MED III (1035.41) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of SOLAR MED III (8.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of SOLAR MED III (5.58) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 311.03. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 9.7x. Operating income very largely covers interest expenses: high safety margin.
311.031
9.709
In 2024, the liquidity ratio of SOLAR MED III (311.03) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of SOLAR MED III (9.7x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 34 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 71 days. Excellent situation: suppliers finance 37 days of the operating cycle (retail model). Overall, WCR represents 68 days of revenue, i.e. 305 k€ to permanently finance. Over 2016-2024, WCR increased by +124%, requiring additional financing.
305 262 €
34 j
71 j
0 j
68 j
Based on 54 transactions of similar company sales
in 2024,
the value of SOLAR MED III is estimated at
3 398 606 €
(range 751 150€ - 6 040 001€).
With an EBITDA of 1 246 405€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SOLAR MED III with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of SOLAR MED III in 2024 is 1.6 M€.
Yes, SOLAR MED III generated a net profit of 339 k€ in 2024.
The headquarters of SOLAR MED III is located in FUVEAU (13710), in the department Bouches-du-Rhone.
The tax return of SOLAR MED III is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SOLAR MED III operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.